NYSEAMERICAN:PTN - Palatin Technologies Stock Price, Forecast & News

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) released its quarterly earnings results on Tuesday, February, 11th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.01) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $4.48 million. During the same period in the previous year, the business earned ($0.02) EPS. View Palatin Technologies' Earnings History.

Palatin Technologies is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Palatin Technologies.

3 analysts have issued 12-month price objectives for Palatin Technologies' shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate Palatin Technologies' share price to reach $3.67 in the next twelve months. This suggests a possible upside of 532.2% from the stock's current price. View Analyst Price Targets for Palatin Technologies.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies.

News headlines about PTN stock have trended neutral on Wednesday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Palatin Technologies earned a news impact score of 0.1 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Palatin Technologies.

Some companies that are related to Palatin Technologies include Volpara Health Tech (VHT), Profound Medical (PRN), Akumin (AKU), Exagen (XGN), Senseonics (SENS), Renalytix Ai (RENX), Oncosil Medical (OSL), Yourgene Health (YGEN), MaxCyte (MXCT), Lexagene (LXG), BARD1 Life Sciences (BD1), Oncimmune (ONC), Sernova (SVA), GeneNews (GEN) and SQI Diagnostics (SQD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include 22nd Century Group (XXII), Heat Biologics (HTBX), Alliqua Biomedical (ALQA), AVEO Pharmaceuticals (AVEO), Progenics Pharmaceuticals (PGNX), ImmunoGen (IMGN), Actinium Pharmaceuticals (ATNM), AcelRx Pharmaceuticals (ACRX), Catalyst Pharmaceuticals (CPRX) and Novavax (NVAX).

Palatin Technologies' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.55%), Acadian Asset Management LLC (1.42%), Strs Ohio (0.34%), AQR Capital Management LLC (0.32%), Bank of New York Mellon Corp (0.24%) and Charles Schwab Investment Management Inc. (0.24%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Institutional Ownership Trends for Palatin Technologies.

PTN stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, New York State Common Retirement Fund, Oxford Asset Management LLP and California Public Employees Retirement System. View Insider Buying and Selling for Palatin Technologies.

PTN stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Acadian Asset Management LLC, Virtu Financial LLC, Strs Ohio, Banque Cantonale Vaudoise, Barclays PLC, UBS Group AG and State Street Corp. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Insider Buying and Selling for Palatin Technologies.

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PTN stock can currently be purchased for approximately $0.58.

Palatin Technologies has a market capitalization of $132.96 million. Palatin Technologies employs 19 workers across the globe.View Additional Information About Palatin Technologies.

The official website for Palatin Technologies is http://www.palatin.com/.

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.